Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A small molecule experimental drug with the molecular formula C14H19BrN2O and average mass of about 311.22 g/mol. It features a brominated aniline core linked to a chiral dimethyl-substituted piperidine via an amide bond. The compound has been investigated for its potential to modulate transcription factors involved in inflammatory and immune responses; specifically noted for suppressing NF-kappa-B activation[2]. No clinical indications or approvals are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}aniline.